semaglutide injection mechanism of action Exploring beyond numeric weight loss: The metabolic effects What is Semaglutide? The Science

Healthcare providers typically evaluate the benefits and risks of treatment when prescribing GLP-1 therapies

The Food and Drug Administration (FDA) has approved three GLP-1s for obesity-related treatment, including Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)

doi: 10.3389/fmicb.2020.00301 176 ZhangY.-G.TanR.-R.RenS.-C.MaX.YanZ.-X.HuaH.et al

& Tuttle, K.R

The study by Riley et al., despite its retrospective design, represents the largest dataset to date, offering robust evidence on cardiovascular and renal outcomes associated with this therapeutic strategy ( Table 3 )

Start Your Transformation Today Kickstart your journey to the best version of YOU